FDA Recall Classes and Procedures: What Medical Device Makers Must Know

What Is a Recall? FDA's Regulatory Definition

The term "recall" has a specific regulatory meaning under 21 CFR Part 7 that is broader than the common understanding of the word. Under FDA regulations, a recall is any action taken to address a problem with a marketed product that violates FDA law or regulations. This includes not just physical removal of devices from the marketplace, but also actions taken to correct a defect in devices still in use with customers.

FDA distinguishes between recalls (where the product is either removed from distribution or corrected in the field), market withdrawals (removal of a product that does not violate FDA regulations), and safety alerts (communications to healthcare providers or users about risks that do not require a device correction or removal). Understanding these distinctions matters because they determine which reporting obligations apply and how FDA oversees the action.

Medical device recalls are governed by 21 CFR Part 806 (Medical Devices: Reports of Corrections and Removals) and Part 810 (Medical Device Recall Authority). Part 806 establishes the manufacturer's reporting obligations when taking voluntary corrective or removal actions. Part 810 establishes FDA's authority to order mandatory recalls when voluntary action is not taken.

The vast majority of medical device recalls are voluntary — initiated by the manufacturer when they discover a problem, often before FDA becomes aware of it. FDA's recall authority (21 CFR Part 810) is used when a manufacturer refuses to voluntarily initiate a recall that FDA believes is necessary to protect public health. In practice, FDA rarely needs to exercise mandatory recall authority because manufacturers typically respond appropriately to FDA concerns.

Recall Classifications: Class I, II, and III

FDA classifies recalls by the severity of the risk posed by the product being recalled. The classification is assigned by FDA after reviewing information submitted by the manufacturer, not by the manufacturer itself.

Class I Recall: The most serious category. A Class I recall involves a situation in which there is reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Class I recalls require the most aggressive recall strategy and receive the most intensive FDA oversight. FDA issues a press release for all Class I recalls.

Examples of situations that typically result in Class I classification: sterility failures in implantable devices, software errors in life-sustaining devices that could cause incorrect dosing, defibrillators with battery failures that could prevent proper defibrillation.

Class II Recall: A recall in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class II recalls cover a wide range of situations — from labeling errors that could cause temporary harm to device performance issues that have low but non-zero probability of serious consequences.

Class III Recall: Use of, or exposure to, a violative product is not likely to cause adverse health consequences. Class III recalls typically involve technical violations of FDA regulations (such as labeling that omits required information) without significant patient safety implications.

Impact of classification on recall strategy: The recall classification directly affects the expected reach of the recall notification, the consignee notification requirements, and the depth of effectiveness checks FDA will require. Class I recalls typically require manufacturer notification to the end-user level (healthcare facility or patient), while Class III recalls may only require notification to direct accounts.

When to Report: 21 CFR Part 806 Reporting Obligations

21 CFR Part 806 requires device manufacturers to report to FDA within 10 working days any correction or removal of a device undertaken to reduce a risk to health posed by the device, or to remedy a violation of the FD&C Act caused by the device.

What constitutes a reportable correction or removal: The reporting obligation is triggered by actions that address safety risks or regulatory violations. Not all product corrections trigger Part 806 reporting — minor corrections undertaken for reasons other than risk reduction or regulatory compliance (such as cosmetic improvements) do not require reporting. However, the threshold for reporting is intentionally low. If there is any question about whether a correction is being undertaken to reduce a health risk, err on the side of reporting.

Non-reportable corrections: Part 806 provides limited exemptions for market withdrawals (where there is no violation or risk) and for recall decisions made by FDA under Part 810 (where FDA directs the recall, the manufacturer's reporting obligation is different).

10-day reporting requirement: The report to FDA must be submitted within 10 working days of deciding to undertake the correction or removal. The report must include: the device identification, the total number of devices subject to the correction or removal, the date the problem was discovered, the manufacturer's assessment of the risk, the action taken, and the contact information for the person submitting the report.

Relationship to complaint handling: The decision to initiate a correction or removal frequently flows from the complaint handling process. When complaint trending, MDR reporting, or a field safety signal indicates a systematic device problem rather than an isolated event, the complaint handling procedure should have explicit triggers and decision criteria for escalating to a recall assessment.

Recall Strategy: What FDA Expects

When a recall is initiated, FDA reviews the manufacturer's proposed recall strategy. The recall strategy must be appropriate to the risk of the device problem and must be effective in reaching all consignees and end-users who have the affected devices.

Recall strategy elements: A complete recall strategy includes: the depth of the recall (to what level in the distribution chain — distributor, healthcare facility, patient/end user), the communication methods that will be used (urgent device correction letters, Dear Healthcare Provider letters, follow-up phone calls), the timeline for communications, and the criteria for determining when the recall is complete.

Consignee lists: The manufacturer must have current, accurate distribution records for all distributed lots of the affected device. If your distribution records are incomplete, your ability to execute an effective recall is compromised. Maintaining accurate, retrievable device distribution records is both a design history requirement (DHR records under QSR/QMSR) and a practical preparedness requirement for recall management.

Effectiveness checks: FDA requires manufacturers to conduct effectiveness checks to verify that recall communications reached their intended recipients and that the requested action was taken. The scope and frequency of effectiveness checks depend on the recall class — Class I recalls typically require much higher effectiveness check coverage than Class III. FDA reviews effectiveness check results and may require additional follow-up if check completion rates are insufficient.

Recall termination: A recall is not closed until FDA terminates it. FDA terminates a recall when it is satisfied that all reasonable efforts have been made to reach all affected consignees and that the risk has been adequately addressed. Premature closure of recall activities before FDA termination is a compliance violation.